Abstract 1629P
Background
TETs are rare malignancies ranging from indolent thymoma (T) A to aggressive thymic carcinoma (TC). The incidence rate of TET ranges from 0.13 to 0.32 per 100 000 person/year, although limited data is available. Because of respiratory complications, patients with COVID-19 infection frequently had chest CT-scan, leading to a potential overdiagnosis of asymptomatic thoracic lesion, including TET. Here, we report the incidence rate of TET by year during first decade of the French RYTHMIC network.
Methods
RYTHMIC is a French network for TETs composed of national and regional expert centers, with the objective of systematic discussion of patient’s management at a single national tumor board, based on consensual guidelines. We conducted a retrospective analysis of patients from RYTHMIC between January 2012 and April 2022. Data were prospectively collected in the registry. We aimed to assess clinic-pathological and epidemiological characteristics of TETs in RYTHMIC cohort.
Results
3667 pts were included in the analysis. The median age at diagnosis was 63.5 (range 9-91). 15% (n=552) of AIDs, mainly myasthenia Gravis (n=411, 74.4%). T B2 was the most frequent (n=540, 14.7%) followed by AB (10.7%), B3 (6.7%), TC (6.6%), B1 (6.3%) and, A (4%). Most of the pts were diagnosed encapsulated (MK I, n=358) or with invasion of the capsule (MK IIa and IIb, n= 308 and 272, respectively). The prevalence of TETs in France based on RYTHMIC nationwide registry was 0.0054% at 30th of March 2022 cut-off. Incidence is shown in the table. In 2020, incidence x 100 000 person/year was 0.97. Table: 1629P
| Year | New patients (N) | France population (M) | Increase of population in France | Incidence x 100.000 inhabitants | Increase incidence in RYTHMIC |
| 2012 | 173 | 65,24 | - | 0,26 | - |
| 2013 | 179 | 65,56 | 0,32 | 0,27 | 0,01 |
| 2014 | 260 | 65,9 | 0,34 | 0,39 | 0,12 |
| 2015 | 320 | 66,42 | 0,52 | 0,48 | 0,09 |
| 2016 | 421 | 66,6 | 0,18 | 0,63 | 0,15 |
| 2017 | 304 | 66,77 | 0,17 | 0,45 | -0,18 |
| 2018 | 358 | 66,99 | 0,22 | 0,53 | 0,08 |
| 2019 | 388 | 67,13 | 0,14 | 0,57 | 0,04 |
| 2020 | 654 | 67,45 | 0,32 | 0,97 | 0,4 |
| 2021 | 338 | 67,62 | 0,17 | 0,49 | -0,48 |
Conclusions
Incidence of TETs in our network is higher than previously reported. In 2020, we observed a pic in the incidence (170% compared to the average rate), potentially due to the COVID induced CT-scans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
RYTHMIC French network.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.